Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.IDRA · Entity 110652 | Director | June 23, 2022 | June 27, 2022 |
| INSMED IncINSM · Entity 3174 | Director | May 13, 2026 | May 15, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Director | June 10, 2026 | June 12, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-06-23 | Direct | 26,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 26,000 · Balance 26,000 F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.
F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.
INSMED Inc
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,622 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 3,305 · Balance 66,622 F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on the first anniversary of the grant date (the Vesting Date), provided that the director (a) remains a member of the Board of Directors of the issuer until the earlier of (i) such Vesting Date and (ii) the Company's Annual Shareholder Meeting in the year of such Vesting Date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2: Each RSU was granted on May 13, 2026, for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on the first anniversary of the grant date (the Vesting Date), provided that the director (a) remains a member of the Board of Directors of the issuer until the earlier of (i) such Vesting Date and (ii) the Company's Annual Shareholder Meeting in the year of such Vesting Date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date.
F2: Each RSU was granted on May 13, 2026, for no consideration.
Immunome Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09 | Direct | 9,897 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FIVE PRIME THERAPEUTICS, INC.
Report date April 16, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-16 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.
F2: Not applicable.
Repare Therapeutics Inc.
Report date January 28, 2026 · Filed January 29, 2026
Section 16 reporting ended · disclosed 2026-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-28 transaction · row 1
1 source rowRow 1 · 2026-01-28 · Disposition to issuer · Disposed 8,000 · Balance 0 F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2029-03-29 | Direct | 0 |
Reported balance
After 2026-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-28 · Disposition to issuer · Disposed 37,941 · Balance 0 F3: This option was cancelled pursuant to the Arrangement Agreement in exchange for (i) $2.20 less the applicable exercise price in respect of such option plus (ii) one CVR per share underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
F3: This option was cancelled pursuant to the Arrangement Agreement in exchange for (i) $2.20 less the applicable exercise price in respect of such option plus (ii) one CVR per share underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 21:45 UTC | Immunome Inc. IMNM · Entity 4219 | GrantDirector Stock Option (right to buy) · Derivative | 9,897 | $0.00 Strike: $18.16 | $0.00 |
DisclosureSEC source: 0001272181-26-000006 · form4-06122026_090636.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,897 Underlying: Common Stock · 9,897 shares Expires 2036-06-09 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 35,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001193125-26-257898 · ownership.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 3,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001272181-26-000004 · wk-form4_1778875679.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,622 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on the first anniversary of the grant date (the Vesting Date), provided that the director (a) remains a member of the Board of Directors of the issuer until the earlier of (i) such Vesting Date and (ii) the Company's Annual Shareholder Meeting in the year of such Vesting Date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2026, for no consideration. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 01:30 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Disposition to issuerStock Option (right to buy) · Derivative | 37,941 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001272181-26-000002 · form4-01282026_080109.xml · derivative · entry 2 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 37,941 shares Expires 2029-03-29 F3 · derivative.exercise_date: This option was cancelled pursuant to the Arrangement Agreement in exchange for (i) $2.20 less the applicable exercise price in respect of such option plus (ii) one CVR per share underlying such option. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 01:30 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | Disposition to issuerCommon Shares | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001272181-26-000002 · form4-01282026_080109.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2 · price: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:58 UTC | Immunome Inc. IMNM · Entity 4219 | GrantDirector Stock Option (right to buy) · Derivative | 18,864 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001415889-25-016990 · form4-06122025_080630.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,864 Underlying: Common Stock · 18,864 shares Expires 2035-06-09 F1 · derivative.exercise_date: The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 28,500 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083038 · ownership.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:57 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-026568 · wk-form4_1747688254.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,317 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:36 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017662 · form4-06202024_080606.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 13, 2024 Filed Jun 19, 2024 00:59 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 11,333 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0001415889-24-017524 · form4-06192024_120638.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,333 Underlying: Common Stock · 11,333 shares Expires 2034-06-12 F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0000950170-24-070699 · ownership.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:21 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023569 · wk-form4_1715804469.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,259 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:37 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 32,934 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-24-000861 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,934 Underlying: Common Stock · 32,934 shares Expires 2034-01-01 F1 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on January 2, 2024 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:32 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-23-036336 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001209191-23-033879 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:25 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018209 · wf-form4_168418233227543.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,097 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2023, for no consideration. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 16:30 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001415889-22-006938 · form4-06272022_040601.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-23 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:53 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001209191-22-038936 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 13, 2022 Filed May 16, 2022 23:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001209191-22-029376 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Shares · 49,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:15 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019178 · form4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,905 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2022, for no consideration. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042792 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001415889-21-002915 · form4-06102021_050601.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-08 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2021 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 8, 2022 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:29 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 46,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001209191-21-038237 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option vests in three equal annual installments commencing on the one year anniversary of the date of grant. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:51 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $32.44 | $0.00 |
DisclosureSEC source: 0001209191-21-032775 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:35 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 7,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017421 · form4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,260 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2021 for no consideration. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:28 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001209191-21-027405 · doc4.xml · derivative · entry 3 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:28 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 1,250 | Not disclosed Strike: $6.09 | Not disclosed |
DisclosureSEC source: 0001209191-21-027405 · doc4.xml · derivative · entry 2 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:28 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $9.17 | Not disclosed |
DisclosureSEC source: 0001209191-21-027405 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:30 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 11,177 | $1.32 | $14,753.64 |
DisclosureSEC source: 0001415889-21-001879 · form4-04052021_040427.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,665 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:39 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 3,620 | $4.02 | $14,552.40 |
DisclosureSEC source: 0001179110-21-000331 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,488 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:07 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 6,111 | $2.25 | $13,749.75 |
DisclosureSEC source: 0001179110-20-010223 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,868 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:59 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 7,681 | $1.79 | $13,748.99 |
DisclosureSEC source: 0001179110-20-008008 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,757 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:58 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | PurchaseCommon Shares | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-20-038973 · doc4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| May 14, 2020 Filed May 15, 2020 17:33 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-20-029806 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 14, 2021 or (ii) the day before the 2021 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| May 12, 2020 Filed May 15, 2020 01:00 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 8,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-061858 · a4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,702 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2020 for no consideration. Read SEC document |
| May 12, 2020 Filed May 19, 2020 19:08 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001179110-20-006351 · edgar.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2030-05-12 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2020 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on May 12, 2021 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 21:46 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 1,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-042576 · a4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on April 1, 2020, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:21 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 10,633 | $1.28 | $13,610.24 |
DisclosureSEC source: 0001179110-20-004667 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,076 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:55 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 5,098 | $2.67 | $13,611.66 |
DisclosureSEC source: 0001104659-19-052801 · a4.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,443 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 16:38 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 5,179 | $2.61 | $13,517.19 |
DisclosureSEC source: 0001179110-19-008387 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,345 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 18:26 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001209191-19-036510 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2029-06-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:07 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001179110-19-007280 · edgar.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2029-06-04 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2019 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 4, 2020 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document |
| May 15, 2019 Filed May 16, 2019 18:42 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001209191-19-030613 · doc4.xml · derivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of May 15, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through each such date. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 17:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 5,166 | $2.59 | $13,379.94 |
DisclosureSEC source: 0001179110-19-004542 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,166 F1 · shares: This stock was issued to the reporting person pursuant to her election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 17:25 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 5,000 | $3.33 | $16,671.00 |
DisclosureSEC source: 0001179110-18-014192 · edgar.xml · nonDerivative · entry 1 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $3.293 to $3.3705 per share. The reporting person hereby undertakes, upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 17:25 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001179110-18-014192 · edgar.xml · derivative · entry 2 SCHAFER CAROL · CIK 0001272181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2028-12-18 F2 · derivative.exercise_date: The option was granted under the Issuer's 2013 Stock Incentive Plan. The option vests and becomes exercisable over a three-year period commencing on December 18, 2018. Thirty-three percent (33%) of the underlying shares vest and become exercisable on December 18, 2019 (first anniversary of the date of grant) with the balance of the underlying shares vesting in eight equal quarterly installments over the remaining two years of the three-year period, subject to continued service with the Issuer. The option automatically becomes exercisable in full upon the occurrence of a change in control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.